JP2019500894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500894A5 JP2019500894A5 JP2018543279A JP2018543279A JP2019500894A5 JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5 JP 2018543279 A JP2018543279 A JP 2018543279A JP 2018543279 A JP2018543279 A JP 2018543279A JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- variant
- seq
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 25
- 230000004048 modification Effects 0.000 claims 25
- 238000012986 modification Methods 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021133074A JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251052P | 2015-11-04 | 2015-11-04 | |
| US62/251,052 | 2015-11-04 | ||
| PCT/US2016/060724 WO2017079694A2 (en) | 2015-11-04 | 2016-11-04 | Chimeric antigen receptors targeting her2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Division JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500894A JP2019500894A (ja) | 2019-01-17 |
| JP2019500894A5 true JP2019500894A5 (enExample) | 2019-12-19 |
| JP6932709B2 JP6932709B2 (ja) | 2021-09-08 |
Family
ID=58662864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543279A Expired - Fee Related JP6932709B2 (ja) | 2015-11-04 | 2016-11-04 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11197919B2 (enExample) |
| EP (2) | EP4074731A1 (enExample) |
| JP (3) | JP6932709B2 (enExample) |
| KR (1) | KR20180083874A (enExample) |
| CN (2) | CN108779174B (enExample) |
| AU (2) | AU2016349722A1 (enExample) |
| BR (1) | BR112018009129A2 (enExample) |
| CA (1) | CA3004306A1 (enExample) |
| ES (1) | ES2909973T3 (enExample) |
| IL (2) | IL259120B (enExample) |
| MX (2) | MX2018005674A (enExample) |
| RU (1) | RU2753695C2 (enExample) |
| WO (1) | WO2017079694A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
| AU2017213661B2 (en) * | 2016-02-05 | 2022-06-02 | City Of Hope | Administration of engineered T cells for treatment of cancers in the central nervous system |
| US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| AU2017384900B2 (en) | 2016-12-28 | 2020-12-10 | GC Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CN111655732B (zh) * | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109608547B (zh) * | 2017-12-29 | 2022-03-15 | 郑州大学第一附属医院 | 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用 |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US20210054409A1 (en) * | 2018-02-09 | 2021-02-25 | National University Of Singapore | Adhesion Receptor Constructs and Uses Thereof in Natural Killer Cell Immunotherapy |
| KR102795055B1 (ko) | 2018-02-11 | 2025-04-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Car-t 세포 및 자가면역 질환 |
| SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| US12448426B2 (en) * | 2018-05-17 | 2025-10-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| WO2020191336A1 (en) | 2019-03-21 | 2020-09-24 | Yamaguchi, Yukiko | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| EP4087867A4 (en) * | 2020-01-23 | 2024-02-14 | Exuma Biotech Corp. | CHIMERIC ANTIGEN RECEPTORS DIRECTED TO HER2 AND METHODS OF USE THEREOF |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4153635A4 (en) * | 2020-05-22 | 2024-06-26 | GC Cell Corporation | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| WO2022187182A1 (en) * | 2021-03-02 | 2022-09-09 | The Trustees Of The University Of Pennsylvania | Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4314040A2 (en) | 2021-03-30 | 2024-02-07 | City of Hope | Car t cell therapy and ifn gamma |
| WO2023274385A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向her2的通用型car-t细胞及其制备方法 |
| KR20240040783A (ko) | 2021-07-29 | 2024-03-28 | 소노마 바이오테라퓨틱스, 인크. | 자가면역 질환을 치료하기 위한 조절 t 세포를 표적화하는 윤활 세포외 기질-특이적 키메라 항원 수용체 |
| JP2024531475A (ja) * | 2021-08-24 | 2024-08-29 | 賽斯尓▲チン▼生物技術（上海）有限公司 | Ｔ細胞製品およびその使用 |
| CN116023491A (zh) | 2021-10-25 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其应用 |
| WO2023172514A1 (en) * | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| WO2023173116A1 (en) | 2022-03-10 | 2023-09-14 | City Of Hope | Membrane-bound il-12 for cellular immunotherapy |
| CN119256075A (zh) * | 2022-04-08 | 2025-01-03 | 菲特治疗公司 | 具有实体瘤靶向骨架的细胞及其用途 |
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| AU2024264153A1 (en) | 2023-04-27 | 2025-11-13 | Vanudis GmbH | Coreceptor chimeric antigen receptor |
| WO2025101672A1 (en) | 2023-11-06 | 2025-05-15 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| CN117924518B (zh) * | 2024-01-05 | 2025-08-22 | 苏州艾凯利元生物科技有限公司 | 用于nk细胞的嵌合抗原受体及工程化的nk细胞 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000061635A2 (en) * | 1999-04-09 | 2000-10-19 | Universität Zürich | Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
| KR20110050567A (ko) * | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法 |
| CA2779526C (en) | 2009-11-03 | 2022-12-06 | City Of Hope | Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection |
| WO2011137245A2 (en) | 2010-04-30 | 2011-11-03 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| US8491908B2 (en) | 2010-06-01 | 2013-07-23 | Canon Kabushiki Kaisha | Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle |
| WO2012050374A2 (en) * | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| DK3424953T3 (en) * | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| AU2013326933B2 (en) | 2012-10-04 | 2017-10-05 | Research Development Foundation | Serine protease molecules and therapies |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| IL238323B2 (en) * | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| JP6285553B2 (ja) * | 2013-08-26 | 2018-02-28 | インノバイオファーム リミテッド | 抗ｃｄ３０キメラ抗原受容体およびその使用 |
| ES2767423T3 (es) * | 2014-01-13 | 2020-06-17 | Hope City | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
-
2016
- 2016-11-04 EP EP22157943.6A patent/EP4074731A1/en not_active Withdrawn
- 2016-11-04 US US15/773,754 patent/US11197919B2/en active Active
- 2016-11-04 KR KR1020187015769A patent/KR20180083874A/ko not_active Ceased
- 2016-11-04 BR BR112018009129-4A patent/BR112018009129A2/pt active Search and Examination
- 2016-11-04 JP JP2018543279A patent/JP6932709B2/ja not_active Expired - Fee Related
- 2016-11-04 ES ES16863128T patent/ES2909973T3/es active Active
- 2016-11-04 CN CN201680076412.0A patent/CN108779174B/zh not_active Expired - Fee Related
- 2016-11-04 CA CA3004306A patent/CA3004306A1/en active Pending
- 2016-11-04 RU RU2018118817A patent/RU2753695C2/ru active
- 2016-11-04 CN CN202211409883.2A patent/CN116063574A/zh active Pending
- 2016-11-04 EP EP16863128.1A patent/EP3371227B8/en active Active
- 2016-11-04 AU AU2016349722A patent/AU2016349722A1/en not_active Abandoned
- 2016-11-04 WO PCT/US2016/060724 patent/WO2017079694A2/en not_active Ceased
- 2016-11-04 MX MX2018005674A patent/MX2018005674A/es unknown
-
2018
- 2018-05-03 IL IL259120A patent/IL259120B/en unknown
- 2018-05-04 MX MX2022013498A patent/MX2022013498A/es unknown
-
2021
- 2021-08-18 JP JP2021133074A patent/JP7264954B2/ja active Active
- 2021-12-06 US US17/543,148 patent/US20220265796A1/en not_active Abandoned
-
2022
- 2022-01-10 AU AU2022200116A patent/AU2022200116A1/en not_active Abandoned
- 2022-04-13 IL IL292222A patent/IL292222A/en unknown
-
2023
- 2023-04-13 JP JP2023065384A patent/JP2023100653A/ja not_active Withdrawn
-
2024
- 2024-10-18 US US18/919,692 patent/US20250333471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500894A5 (enExample) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| JP2017537627A5 (enExample) | ||
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| RU2685479C2 (ru) | Химерный антигенный рецептор | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| ES2959480T3 (es) | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo | |
| ES2848478T3 (es) | Receptores quiméricos para antígenos y usos de estos | |
| JP2015518479A5 (enExample) | ||
| JP2017500869A5 (enExample) | ||
| JP2019528078A (ja) | 細胞治療のための構造的に活性なサイトカイン受容体 | |
| RU2016143384A (ru) | Трансгенные генетические метки и способы применения | |
| JP2016520074A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| JP2016538855A5 (enExample) | ||
| CN108779160A (zh) | 施用工程化t细胞以治疗中枢神经系统中的癌症 | |
| JPWO2020014366A5 (enExample) | ||
| Wang et al. | Minicircle DNA-mediated CAR T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo | |
| JP2019512251A5 (enExample) | ||
| CN105802909A (zh) | 具有her2特异性tcr的t细胞制备物及其用途 |